Form 4: Theravance Biopharma SVP Rhonda Farnum Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Rhonda Farnum, SVP at Theravance Biopharma, reports disposing of 9,120 ordinary shares to cover tax obligations arising from vesting restricted stock units.
Summary
- On May 20, 2025, Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, disposed of 9,120 ordinary shares.
- The shares were withheld to satisfy tax obligations related to the vesting of previously granted restricted stock units.
- The transaction was conducted with the issuer and did not involve an open market transaction.
- Following the transaction, Farnum beneficially owns 360,918 ordinary shares.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It reflects standard executive compensation practices.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and tax obligations, common in the biopharmaceutical industry.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of transaction: Disposal of ordinary shares. |
| 05/22/2025 | Date of signature on the report. |
Keywords
Theravance Biopharma, Form 4, Rhonda Farnum, Share Disposal, Tax Obligations, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.